Intratumoral Therapy Increases Response to Checkpoint Inhibitor in Triple Negative Breast Cancer, Study Finds
News
Combining OncoSec Medical‘s intratumoral therapy, ImmunoPulse IL-12, with an immune checkpoint inhibitor is a promising approach for triple-negative breast cancer patients, a Phase 1 clinical trial suggests. The approach induced robust ... Read more